edotreotide has been researched along with Kidney Failure, Chronic in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cybulla, M; Otte, A; Weiner, SM | 3 |
| Brunner, FP; Maecke, HR; Mihatsch, MJ; Moll, S; Mueller-Brand, J; Nickeleit, V | 1 |
| Maecke, H; Mueller-Brand, J; Schumacher, T; Waldherr, C | 1 |
5 other study(ies) available for edotreotide and Kidney Failure, Chronic
| Article | Year |
|---|---|
90Y-DOTATOC and nephrotoxicity.
Topics: Animals; Carcinoid Tumor; Humans; Intestinal Neoplasms; Kidney; Kidney Failure, Chronic; Octreotide; Radiopharmaceuticals; Radiotherapy Dosage; Yttrium Radioisotopes | 2002 |
A new cause of renal thrombotic microangiopathy: yttrium 90-DOTATOC internal radiotherapy.
Topics: Biopsy; Carcinoma, Neuroendocrine; Female; Humans; Kidney; Kidney Diseases; Kidney Failure, Chronic; Male; Middle Aged; Octreotide; Radiation Injuries; Thrombosis; Yttrium Radioisotopes | 2001 |
End-stage renal disease after treatment with 90Y-DOTATOC.
Topics: Aged; Carcinoid Tumor; Female; Humans; Intestinal Neoplasms; Kidney Failure, Chronic; Octreotide; Radiopharmaceuticals | 2001 |
Is (90)Y-DOTATOC treatment for neuroendocrine tumours safe?
Topics: Animals; Antineoplastic Agents, Hormonal; Carcinoma, Medullary; Humans; Hypertension, Renal; Kidney Failure, Chronic; Neuroendocrine Tumors; Octreotide; Radiopharmaceuticals; Receptors, Somatostatin; Thyroid Neoplasms; Yttrium Radioisotopes | 2002 |
Kidney failure after treatment with 90Y-DOTATOC.
Topics: Aged; Carcinoid Tumor; Female; Humans; Intestinal Neoplasms; Kidney Failure, Chronic; Octreotide; Radiation Injuries; Yttrium Radioisotopes | 2002 |